Skip to content
Screener

Lightpath Technologies LPTH Temporary Equity Offering Costs

Temporary Equity Offering Costs at other companies

Regenxbio logo
RegenxbioRGNX
$124.75K-20.5%
Regenxbio logo
RegenxbioRGNX
$124.75K-20.5%
CEP
CEPTCEPT
$5.3M+19,713%
CEP
CEPTCEPT
$5.3M+19,713%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$180K-169%
Rapport Therapeutics, Inc. logo
Rapport Therapeutics, Inc.RAPP
-$180K-169%

Other financials

Income statement

See full
Revenue$19.1M+109%
Gross profit$4.5M+57.6%
Operating income-$2.5M-82.0%
Net income-$4.1M-14.6%
EPS (diluted)-$0.07-75.0%

Balance sheet

See full
Cash & equivalents$55.2M+753%
Total debt$11.4M-20.7%
Total equity$89.1M+467%
Total assets$144.3M+77.2%

Cash flow

See full
Operating cash flow-$6.8M-110%
CapEx$899.5K+114%
Free cash flow-$7.7M-110%

Valuation

See full
Market cap$789.26M+404%
Enterprise value$745.41M+360%
P/S12.6×+8.4×

Profitability

See full
Gross margin26.8%-1.7pp
Operating margin-29.5%+6.9pp
Net margin-37.4%+11.5pp
FCF margin-16.4%-2.1pp

Returns & leverage

See full
Return on equity-44.8%+2.1pp
Debt / equity0.1×-0.8×
Current ratio3.9×+1.6×

Where this comes from

Reported directly by Lightpath Technologies in its filing.

Tagged under the XBRL concept lpth:TemporaryEquityOfferingCosts.

The source filing: Lightpath Technologies’s 10-K, filed September 26, 2025.

Filed
Sep 26, 2025
Fiscal year
FY2025
Accession
0001654954-25-011130

Offering costs – The $2.0 million of estimated direct and incremental offering costs in connection with the Acquisition Financing, allocated based on the relative fair values of the warrants, Class A Common Stock, Series G Convertible Preferred Stock and the Acquisition Notes that comprise the offering. Issuance costs were allocated as follows: (i) $1.6 million allocated to the Series G Convertible Preferred Stock and the Class A Common Stock issued in conjunction with the Acquisition Financing were recorded as a reduction to temporary equity; (ii) $0.3 million allocated to the warrants were expensed, as the warrants were determined to be classified as a liability, initially; and (iii) $0.3 million allocated to the Acquisition Notes, which are deferred and will be expensed over the term of the Acquisition Notes using the effective interest method.

Item 16. Form 10-K Summary.

FAQ

What is Lightpath Technologies's temporary equity offering costs?
Lightpath Technologies (LPTH) reported temporary equity offering costs of $75K in Q2 2025.
What does temporary equity offering costs mean?
Reflects the direct costs incurred in connection with the issuance of equity securities, such as underwriting fees, legal expenses, and registration costs. Monitoring these costs helps assess the efficiency of the company's capital-raising activities.

Ask your AI about Lightpath Technologies's temporary equity offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude